| Brand Name | Ilumya |
| Generic Name | Tildrakizumab |
| Drug Class | Anti-IL-12/IL-23 Monoclonal Antibody |
| Availability | Prescription |
| Manufacturer | Merck & Co. |
| Indications | Ulcerative Colitis, Crohn's Disease |
| Type | Injection |
| Doses | 100 mg at weeks 0, 4, then every 12 weeks for maintenance. |
| Route | Subcutaneous |
| Side Effects | Injection site pain, upper respiratory infections, diarrhea |
| Interactions | IL-23 inhibitor; monitor for infections and hypersensitivity |
| Overdose | Infections, injection-site reactions. |
| Missed Dose | Take ASAP or at next scheduled dose. |
| Contraindications | Hypersensitivity, active infection, caution in liver disease. |
| Alternatives | Vedolizumab |
| Co-Pay Assistance Program | Available Rx |
| Patient Assistance Program | Available |
Dr. Bharat Pothuri is a Board-Certified Gastroenterologist and Hepatologist. With extensive experience in digestive health, he specializes in advanced endoscopic procedures, chronic GI disorder management, and preventive care. Dr. Pothuri is dedicated to providing expert, patient-focused insights to help improve gut health and overall well-being.
Tildrakizumab is a drug, used in curing moderate to severe psoriasis of the skin by inhibiting the production of interleukin-23 (IL-23) that brings out skin inflammation.
The mechanism of action of Tildrakizumab is premised on the fact according to which this drug binds to the IL-23 and the protein which is involved in the inflammation process and, therefore, possibly, inhibits the excessive production of skin cells which is the cause of the psoriasis exacerbation.
Side effects are also typical including headache and fatigue, and upper respiratory infections. The drastic side effects can be infections and allergies.
Tildrakizumab is a subcutaneous injection that has the average interval of 12 weeks in addition to the initial injections. Your response will be dictated by your doctor and will then be the basis of the schedule.
Yes, Tildrakizumab can be predisposing to infection due to being an immunosuppressive agent. Your physician should regularly visit you to have an opportunity to cure the infections on time.
Tildrakizumab in pregnancy should only be employed when it is more prone to lead to the gain of weight than the chances of getting the risks. Consultation should be done with your medical practitioner especially when pregnant or during pregnancy.
Tildrakizumab has great potential in the management of moderate and severe cases of plaque psoriasis since a substantial number of patients have indicated that the drug has high skin effects.
Do not forget to take a dose, remind your care giver about it. Do not skip the drug dose.
Tildrakizumab is primarily used to treat psoriasis, however, still, it is under study as a treatment of other forms of inflammatory diseases, including psoriatic arthritis.
Tildrakizumab may be applied alongside other immunosuppressives. Another reason is that you should never forget to tell your health provider about all the medications that you take.
Related Conditions |
Related Blogs |
|---|---|
